Genomic Health, Inc. (NASDAQ:GHDX)‘s stock had its “hold” rating reissued by stock analysts at Jefferies Group LLC in a note issued to investors on Thursday. They currently have a $33.00 price target on the medical research company’s stock. Jefferies Group LLC’s target price suggests a potential upside of 6.59% from the stock’s current price.

Other analysts have also issued research reports about the stock. Canaccord Genuity cut their price objective on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, August 15th. Cowen and Company reissued a “hold” rating and issued a $34.00 price objective on shares of Genomic Health in a research report on Friday, September 1st. BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Piper Jaffray Companies reissued a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research report on Thursday, August 3rd. Finally, Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. Genomic Health currently has an average rating of “Hold” and an average price target of $32.00.

Genomic Health (GHDX) traded down 1.68% on Thursday, hitting $30.96. 132,220 shares of the stock were exchanged. The stock’s market capitalization is $1.07 billion. The company has a 50 day moving average of $31.03 and a 200 day moving average of $31.60. Genomic Health has a one year low of $26.37 and a one year high of $33.97.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). The business had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.18) EPS. On average, equities research analysts forecast that Genomic Health will post ($0.01) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Genomic Health, Inc. (GHDX) Earns “Hold” Rating from Jefferies Group LLC” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/14/genomic-health-inc-ghdx-earns-hold-rating-from-jefferies-group-llc.html.

In other Genomic Health news, insider Steven Shak sold 5,000 shares of the company’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $33.27, for a total transaction of $166,350.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kimberly J. Popovits sold 1,468 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $32.67, for a total transaction of $47,959.56. The disclosure for this sale can be found here. Insiders have sold 37,642 shares of company stock worth $1,195,131 over the last ninety days. Insiders own 46.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wetherby Asset Management Inc. raised its position in Genomic Health by 3.7% during the second quarter. Wetherby Asset Management Inc. now owns 8,912 shares of the medical research company’s stock worth $290,000 after acquiring an additional 317 shares in the last quarter. Dubuque Bank & Trust Co. raised its position in Genomic Health by 8.4% during the second quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock worth $159,000 after acquiring an additional 379 shares in the last quarter. Parametric Portfolio Associates LLC raised its position in Genomic Health by 5.8% during the second quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after acquiring an additional 441 shares in the last quarter. Bank of New York Mellon Corp raised its position in Genomic Health by 0.6% during the first quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock worth $2,789,000 after acquiring an additional 500 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Genomic Health by 3.4% during the second quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock worth $516,000 after acquiring an additional 520 shares in the last quarter. 88.91% of the stock is currently owned by hedge funds and other institutional investors.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.